World Conference on Lung Cancer & ESMO Congress 2018
Scientific Summaries
Two of the most important conferences in non-small cell lung cancer (NSCLC) – the IASLC 19th World Conference on Lung Cancer (WCLC) and the ESMO Congress 2018 – are happening this fall. WCLC 2018 takes place September 23rd to 26th in Toronto, Canada, immediately followed by ESMO 2018 on October 19th to 23rd in Munich, Germany. M.D. /alert has compiled extensive coverage of the most important research, presentations, and breaking news unveiled at both WCLC 2018 and ESMO 2018, in order to keep clinicians up-to-date on the data that could change the standard of care for NSCLC.
ESMO 2018: Pembrolizumab Extends Quality Survival in NSCLC
October 28, 2018
A new analysis of the KEYNOTE 024 and KEYNOTE 010 trials found that patients who receive pembrolizumab not only live longer, they...
.jpg "Brigatinib Superior to Crizotinib for Frontline ALK+ NSCLC")
Brigatinib Superior to Crizotinib for Frontline ALK+ NSCLC
November 8, 2018First-line treatment with brigatinib appeared superior to crizotinib for the treatment of adults with anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC)...
.jpg "72% of NSCLC Patients with MET Mutation Respond to Capmatinib")
72% of NSCLC Patients with MET Mutation Respond to Capmatinib
November 2, 2018The Phase II GEOMETRY mono-1 study found that nearly three-quarters of treatment-naïve patients responded to capmatinib, a selective MET inhibitor...
ESMO 2018: Pembrolizumab Extends Quality Survival in NSCLC
October 28, 2018A new analysis of the KEYNOTE 024 and KEYNOTE 010 trials found that patients who receive pembrolizumab not only live longer, they...
.jpg "Immunotherapy with Pembrolizumab Improves Head/Neck Cancer Survival")
Immunotherapy with Pembrolizumab Improves Head/Neck Cancer Survival
October 25, 2018According to a breaking presentation from ESMO Congress 2018 in Munich, immunotherapy with pembrolizumab demonstrated increased survival in patients with recurred or metastasized...
.jpg "Neoadjuvant Erlotinib Improves PFS in mutated-NSCLC")
Neoadjuvant Erlotinib Improves PFS in mutated-NSCLC
October 25, 2018A presentation at ESMO Congress 2018 in Munich determined that neoadjuvant erlotinib benefited a subset of patients with early-stage EGFR-mutated non-small cell lung cancer...
